More Biopharmaceuticals Webinars
Our webinars keep you informed on the latest products and technologies, current industry topics, the latest trends and a range of innovations and solutions to help continuously improve your processes.
February 2018

Following recent mainstream media coverage of reported supply and demand mismatch, viral vectors now dominate much of the discussion within the cell and gene therapy sector. This panel webinar will provide insight from three leading experts at the forefront of vector manufacturing, as they share their first-hand experiences in moving to commercial-scale manufacture of viral vectors.

Register
December 2017

Learn how traditional low pH virus inactivation has been translated into an automatic system.

 

See the two methods used for validating the system design, and an overview of the integration of capture chromatography and virus inactivation

Watch
November 2017

The Cadence™ Virus Inactivation (VI) system, a fully automated low pH virus inactivation system for both batch and continuous processing is one of the latest additions to Pall’s Continuous platform.  This webinar will discuss how traditional low pH virus inactivation has been translated into an automatic system, and also the additional challenges associated with making it a continuous process.  There will be a review of the two methods used for validating the design and an overview of the integration of capture chromatography and virus inactivation, which represents the first commercial scale combined unit operations in this space.

Watch

Learn the findings of the full-factorial modeling exercise

Understand the cost benefits of continuous bioprocessing at many scales of manufacturing.

Watch
September 2017
Virus Filtration in Continuous Processing

Biopharmaceuticals webinar series

  • Learn how to implement Quality by Design (QbD) principles, and process validation strategies for continuous virus filtration
  • See the process inputs that should be evaluated to determine critical process parameters
  • Learn how a Pegasus™ Prime virus filter achieves high virus retention and delivers a robust and efficient continuous process
Watch
July 2017

We address optimal configuration of a multi-column continuous chromatography (MCC) system, with insight into the impact antibody titer has on the number of chromatography columns required to optimize productivity of a MCC process.
 

Continuous multi-column chromatography (MCC) has been gaining increasing interest as an enabling bioprocessing technique that allows for increases in specific productivity (g/L/hr) and operating binding capacity (g mAb/L sorbent) over traditional batch solutions. With recent advances, users have reported an increase in cost savings stemming from reduced resin volumes, lower buffer consumption, and increased resin usage.
 

Mark Pagkaliwangan presents, with David Johnson moderating, as they discuss MCC solution advances with processes utilizing two columns or more. They will explore how the total number of columns used in a process can affect performance, and how titer and flowrate can be optimized with more columns for greater efficiency and productivity.
 

Watch
  • Learn how to reduce facility footprint, capital expenses and product cost-of-goods
  • See how you can improve your process productivity, flexibility, and further facilitate the utilization of single-use and/or disposable technologies
     

Continuous bioprocessing for biologics manufacturing is being adopted in the biopharmaceutical industry. Pall Life Sciences has brought several innovative technology platforms to the market to address the opportunities for Continuous Bioprocessing. In this webinar, Pall’s development journey in continuous bioprocessing will be introduced along with highlights of recent technology advances and product introductions for both PD and GMP operations.

Watch

We address optimal configuration of a multi-column continuous chromatography (MCC) system, with insight into the impact antibody titer has on the number of chromatography columns required to optimize productivity of a MCC process.

MCC  has been gaining increasing interest as an enabling bioprocessing technique that allows for increases in specific productivity (g/L/hr) and operating binding capacity (g mAb/L sorbent) over traditional batch solutions. With recent advances, users have reported an increase in cost savings stemming from reduced resin volumes, lower buffer consumption, and increased resin usage.
 

Mark Pagkaliwangan presents, with David Johnson moderating, as they discuss MCC solution advances with processes utilizing two columns or more. They will explore how the total number of columns used in a process can affect performance, and how titer and flowrate can be optimized with more columns for greater efficiency and productivity.

Watch
  • Results of experimental findings and insights from execution of both the BPOG and USP <665> extractables protocols on multiple single-use components including similarities and differences in extraction profiles
  • Details of case studies illustrating how Pall’s growing portfolio of BPOG extractables datasets can be used to help support component qualification and overall toxicological risk assessment for single-use systems
Watch
June 2017
  • Results of experimental findings and insights from execution of both the BPOG and USP <665> extractables protocols on multiple single-use components including similarities and differences in extraction profiles
  • Details of case studies illustrating how Pall’s growing portfolio of BPOG extractables datasets can be used to help support component qualification and overall toxicological risk assessment for single-use systems
Watch